GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » Debt-to-Revenue

Artgen Biotech PJSC (MIC:ABIO) Debt-to-Revenue : 0.65 (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Artgen Biotech PJSC's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was ₽101 Mil. Artgen Biotech PJSC's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was ₽711 Mil. Artgen Biotech PJSC's annualized Revenue for the quarter that ended in Jun. 2023 was ₽1,242 Mil. Artgen Biotech PJSC's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 was 0.65.


Artgen Biotech PJSC Debt-to-Revenue Historical Data

The historical data trend for Artgen Biotech PJSC's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC Debt-to-Revenue Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.51 0.45 0.52 0.73

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.49 0.60 0.67 0.65

Competitive Comparison of Artgen Biotech PJSC's Debt-to-Revenue

For the Biotechnology subindustry, Artgen Biotech PJSC's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artgen Biotech PJSC's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Artgen Biotech PJSC's Debt-to-Revenue falls into.



Artgen Biotech PJSC Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Artgen Biotech PJSC's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(118.862 + 712.738) / 1136.904
=0.73

Artgen Biotech PJSC's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(100.524 + 711.16) / 1242.23
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.


Artgen Biotech PJSC Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Artgen Biotech PJSC (MIC:ABIO) Business Description

Traded in Other Exchanges
N/A
Address
Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.